Business Context and Reporting Period
Company: Benchmark Electronics, Inc. (BHE)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2024
Business Overview: Benchmark provides advanced manufacturing services, design and engineering, and technology solutions to OEMs in sectors including semiconductor capital equipment, complex industrials, medical technologies, aerospace & defense (A&D), and advanced computing & communications (AC&C). Operations are located in the Americas, Asia, and Europe.
Key Financial Metrics
| Metric (in thousands) | Q2 2024 | Q2 2023 | 6M 2024 | 6M 2023 |
|---|---|---|---|---|
| Sales | $665,896 | $733,232 | $1,341,471 | $1,427,927 |
| Gross Profit | $67,950 | $67,031 | $135,358 | $130,989 |
| Gross Margin | 10.2% | 9.1% | 10.1% | 9.2% |
| Income from Operations | $27,253 | $24,481 | $52,782 | $47,223 |
| Net Income | $15,528 | $13,991 | $29,530 | $26,351 |
| Diluted EPS | $0.43 | $0.39 | $0.81 | $0.74 |
| Operating Cash Flow (6M) | $104,274 (2024) vs. $(368) (2023) | |||
| Cash & Equivalents (End of Period) | $309,287 | |||
| Total Debt (Current + Long-term) | $289,485 |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2024 sales decreased 9% year-over-year (YoY) to $665.9 million. The six-month decline was 6% to $1.34 billion.
- Profitability Improvement: Despite lower revenue, Net Income increased 11% in Q2 and 12% for the six months. Gross margin expanded to 10.2% in Q2 from 9.1% in Q2 2023, driven by operational efficiencies and cost reduction actions.
- Segment Performance:
- Increases: Semi-Cap (+5% Q2), A&D (+36% Q2), and Europe (+15% Q2) saw revenue growth.
- Decreases: Medical (-23% Q2), AC&C (-26% Q2), and Complex Industrials (-15% Q2) declined due to end-demand softness and inventory re-balancing.
- Cash Flow: Operating cash flow improved significantly to $104.3 million for the six months ended June 30, 2024, compared to a negative $0.4 million in the prior year period, largely due to a $71.3 million decrease in accounts receivable and an $82.7 million decrease in inventories.
- Restructuring: The company recognized $4.8 million in restructuring charges for the six months ended June 30, 2024, primarily related to capacity and workforce reductions in the Americas.
Guidance, Outlook, and Risks
- Outlook: Management expects capital expenditures to approximate $60 million to $70 million over the next 12 months to support production capacity. No specific numerical revenue or earnings guidance was provided in the text.
- Dividends: The Board declared a quarterly dividend of $0.165 per share for Q2. Effective July 30, 2024, the quarterly dividend was increased to $0.17 per share.
- Share Repurchases: No shares were repurchased during the six months ended June 30, 2024. Approximately $154.6 million remains available under current authorizations.
- Tax Environment: The effective tax rate increased to 24.3% in Q2 2024 from 21.9% in Q2 2023 due to the expiration of tax incentives in China, GILTI impacts, and the implementation of the Global Minimum Tax (GMT).
- Risks:
- Supply Chain: Constraints on older technology semiconductors may limit production capacity despite easing in other categories.
- Customer Concentration: Sales to the ten largest customers represented 53% of total sales for the six months ended June 30, 2024.
- Geopolitical & FX: Exposure to foreign currency fluctuations and geopolitical tensions affecting international operations.
Investor Verification Checklist
- Inventory Levels: Verify the sustainability of the $82.7 million inventory reduction and its impact on future working capital needs.
- Customer Concentration: Assess the risk associated with 53% of revenue coming from the top ten customers.
- Tax Rate Volatility: Monitor the impact of expiring tax holidays (China, Malaysia) and the Global Minimum Tax on future effective tax rates.
- Debt Covenants: Confirm continued compliance with interest coverage and debt leverage covenants under the $550 million revolving credit facility.
- Segment Mix: Evaluate the long-term trend of declining Medical and AC&C revenue versus growth in Semi-Cap and A&D.